Apomab

Apomab is a fully human agonistic monoclonal antibody designed to specifically bind to and activate the human Apo2L/TRAIL death receptor DR5. This activation triggers apoptosis through the extrinsic apoptotic signaling pathway, leading to programmed cell death in cancer cells. It has demonstrated potent antitumor activity in preclinical models against breast cancer, colorectal cancer, non-small cell lung carcinoma, and pancreatic cancer, while sparing normal cells. Developed by Genentech, Apomab has progressed to Phase II clinical trials for various malignancies, including breast cancer, and has shown promise in treating primary and metastatic disease, particularly in preventing and resolving cancer-induced osteolysis.

Brand names

Apomab

Other names

drozitumabanti-DR5 mAbanti-DR-5 mAbanti-DR 5 mAbanti-death receptor 5 monoclonal antibodyanti-TRAIL receptor-2 monoclonal antibody